Saturday 17 October 2026
Export SYBX’s income statement to Excel — free account
Synlogic, Inc.
SYBX Healthcare Biotechnology
Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.00
0.08
−7.41%
Follow SYBX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (5.32%) | (5.00%) | (8.17%) | (27.54%) |
+8 more TTM periods Free account |
|
| (4.25%) | (3.94%) | (5.70%) | (17.30%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(5.47%) | (5.13%) | (8.51%) | (31.41%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.31) | (0.27) | (0.34) | (0.31) | |
Free Cash Flow |
(3.84) | (3.32) | (4.19) | (3.81) | |
Capital Expenditures |
— | — | 0.17 | 0.20 | |
| Other line items | |||||
Cash ROIC |
(15.25%) | (12.46%) | (15.80%) | (14.69%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
5.87 | 5.18 | 4.34 | 1.24 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.31) | (0.27) | (0.35) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.02 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates